{"id":"lacidipine-amlodipine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Peripheral edema"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Flushing"},{"rate":"3-10","effect":"Dizziness"},{"rate":"2-5","effect":"Palpitations"}]},"_chembl":{"chemblId":"CHEMBL460291","moleculeType":"Small molecule","molecularWeight":"455.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both agents block the influx of calcium ions through voltage-gated L-type calcium channels in the cell membrane of vascular smooth muscle cells. This prevents smooth muscle contraction and causes peripheral vasodilation, reducing systemic vascular resistance and lowering blood pressure. Amlodipine has a longer half-life and slower onset than lacidipine, allowing for once-daily dosing.","oneSentence":"Lacidipine and amlodipine are dihydropyridine calcium channel blockers that inhibit L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:19.765Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT00338338","phase":"PHASE4","title":"The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-07","conditions":"Uncomplicated Hypertension, Hypertension, Essential","enrollment":70},{"nctId":"NCT00460915","phase":"PHASE4","title":"Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean ISH Patients Aged 60 to 80 Years","status":"COMPLETED","sponsor":"Korea University Guro Hospital","startDate":"2007-01","conditions":"Hypertension","enrollment":204}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":82,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lacidipine & Amlodipine","genericName":"Lacidipine & Amlodipine","companyName":"Korea University Guro Hospital","companyId":"korea-university-guro-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lacidipine and amlodipine are dihydropyridine calcium channel blockers that inhibit L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reducing blood pressure. Used for Hypertension, Angina pectoris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}